Opko Health Inc (OPK)

[WiseFool]

What is so disingenuous about the Editor of Barron's Bill Alpert’s article is that it mimics his first 2012 article on Opko titled "Sweating Out the Results of a Blood Test."

Opko was sell for around $4.18 when the first article was published. It's was a bullish no-brainer then as it is today. Alpert's myopic statement in his first article, as in his second, only cements my conviction that someday Opko will be a Major Pharm Company.

It's kind of comical that Alpert issued a backtrack response to his viewers pertaining to his first article. Seems like his concerns about disgruntled Barron Subscribers outweighed his lack of due diligence on the Opko Fundamental's at hand. Below is the original response to the first piece titled: "Sweating Out the Results of a Blood Test."

Excerpt from: (Barron's “Sweating Out the Results of a Blood Test,” Oct. 1, 2012)

"Opko’s other leading diagnostics program is a prostate-cancer test that screens for three additional biomarkers along with the standard prostate-specific antigen. Frost said the test was Opko’s nearest hope for large revenue and profits. A May 2010 Journal of Clinical Oncology report by the test’s developers claimed that their four-marker test would reduce unnecessary biopsies by half. However, an accompanying editorial in the same issue pointed out that the new screen was less sensitive than existing tests—failing to detect 14% of high-grade cancers—and was not likely to change prostate-cancer mortality."


Barron's Bill Alpert response to his highly critical viewer's:


So as you can see, all of the Barron Bunk that was printed back in 2012 turned out to be erroneous. I still think it resembles the markings of a desperate short seller. With yesterday's stellar recommendation from the National Comprehensive Cancer Network Guidelines for Prostate Cancer Early Detection, Opko Health is definitely on it's way to big and better times.